Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer

Carolin Grunwald1, Michael Koslowski, Tülin Arsiray

  • 1Department of Internal Medicine III, Johannes Gutenberg-University, Langenbeckstr. 1, 55131 Mainz, Germany, and University Hospital Ghent, Belgium.

Insights

Cancer/germline (CG) antigens are promising targets for nonsmall cell lung cancer (NSCLC) vaccines. Most NSCLC express multiple CG genes, suggesting combination therapies could benefit more patients.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Cancer/germline (CG) antigens are potential targets for cancer vaccines in nonsmall cell lung cancer (NSCLC).
  • Limited data exists on the combined expression of CG antigens in NSCLC.
  • Understanding CG antigen expression is crucial for developing effective NSCLC immunotherapies.

Purpose of the Study:

  • To analyze the expression of seven CG genes in human NSCLC specimens.
  • To determine the frequency and patterns of CG gene expression in different NSCLC subtypes.
  • To explore the potential for combination CG antigen-based therapies in NSCLC.

Main Methods:

  • Analysis of 7 CG genes (MAGE-A3, NY-ESO-1, LAGE-1, BRDT, HOM-TES-85, TPX-1, LDHC) in 102 NSCLC specimens.
  • Assessment of gene expression patterns and correlation with NSCLC subtypes (squamous cell carcinoma vs. adenocarcinoma).
  • Investigation of genomic methylation's role in CG gene regulation.

Main Results:

  • 81% of NSCLC specimens expressed at least one CG gene; 50% expressed at least two.
  • CG gene activation was more frequent in squamous cell carcinoma than in adenocarcinomas.
  • Most analyzed CG genes were regulated by genomic methylation, but not all were co-expressed.

Conclusions:

  • A significant proportion of NSCLC patients express multiple CG antigens, supporting the development of multiantigen vaccines.
  • Combining CG genes not located on the X-chromosome may broaden treatment applicability for NSCLC patients.
  • Targeting specific combinations of CG antigens holds promise for more effective NSCLC treatment strategies.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...